oldrunnerguy
GLP-1 Apprentice
I tried to use the 'not behind a paywall link' here.
This article, published on March 19, 2026, details the breakthrough Phase 3 results for Eli Lilly’s investigational drug, retatrutide, which showed unprecedented efficacy in treating both type 2 diabetes and obesity.
The key findings from the TRANSCEND-T2D-1 trial highlighted in the report include:
This article, published on March 19, 2026, details the breakthrough Phase 3 results for Eli Lilly’s investigational drug, retatrutide, which showed unprecedented efficacy in treating both type 2 diabetes and obesity.
The key findings from the TRANSCEND-T2D-1 trial highlighted in the report include:
- Triple-Hormone Mechanism: Unlike existing drugs like Wegovy (which targets GLP-1) or Mounjaro (which targets GLP-1 and GIP), retatrutide is a "triple agonist." It targets three hormones—GLP-1, GIP, and glucagon. The addition of glucagon is believed to boost energy expenditure, leading to superior results.
- Significant Weight Reduction: Participants with type 2 diabetes taking the highest dose (12 mg) lost an average of 36.6 pounds (16.8% of their body weight) over just 40 weeks. This significantly outpaces results typically seen in diabetes-focused trials for earlier-generation drugs.
- Blood Sugar Control: The drug "slashed" blood sugar levels, with A1C reductions ranging from 1.7% to 2.0%. At the start of the trial, participants had an average A1C of 7.9%.
- Comparison to Competitors: Analysts noted that these figures position retatrutide as a more potent option than Lilly’s own Mounjaro and Novo Nordisk’s Wegovy, particularly for patients where maximal weight loss is a primary goal alongside glycemic control.
- Side Effects & Safety: The most common adverse events were gastrointestinal (nausea, vomiting, and diarrhea), primarily occurring during the dose-escalation phase. The trial also monitored a safety signal called dysesthesia (an abnormal skin sensitivity), which occurred in roughly 4% of participants.
Last edited:
